

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6375460

| | |
|---|-------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| REDOX SRL | 05/17/2016 |
| RECEIVING PARTY DATA | |
| Name: | TONIX PHARMACEUTICALS, INC. |
| Street Address: | 509 MADISON AVENUE, SUITE 306 |
| City: | NEW YORK |
| State/Country: | NEW YORK |
| Postal Code: | 10022 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 17082949 |
| CORRESPONDENCE DATA | |
| Fax Number: | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Email: | MARIA.MARLEY@HGLAW.COM |
| Correspondent Name: | HALEY GUILIANO LLP |
| Address Line 1: | 75 BROAD STREET, SUITE 1000 |
| Address Line 4: | NEW YORK, NEW YORK 10004 |
| ATTORNEY DOCKET NUMBER: | 104545-0008-306 |
| NAME OF SUBMITTER: | MARIA E. MARLEY |
| SIGNATURE: | /MARIA E. MARLEY/ |
| DATE SIGNED: | 10/29/2020 |
| Total Attachments: 6 | |
| source=104545-0008-306-Redox-TPI#page1.tif | |
| source=104545-0008-306-Redox-TPI#page2.tif | |
| source=104545-0008-306-Redox-TPI#page3.tif | |
| source=104545-0008-306-Redox-TPI#page4.tif | |
| source=104545-0008-306-Redox-TPI#page5.tif | |
| source=104545-0008-306-Redox-TPI#page6.tif | |

ASSIGNMENT

We, REDOX srl, known as REDOX snc prior to April 15, 2014, having an office and a place of business at Viale Stucchi 62/26, 20900 Monza (MI), Italy, for good and valuable consideration, including consideration of one Euro (€1.00), receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to TONIX PHARMACEUTICALS, INC. having an office and a place of business at 509 Madison Avenue, Suite 306, New York, NY 10022, United States of America, its successors and assigns (1) the entire right, title and interest in the United States and in all countries throughout the world in and to any and all our inventions and discoveries disclosed in the following applications:

- (i) United States Provisional Application No. 61/792,757, filed March 15, 2013 and entitled "Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride";
- (ii) A United States non-provisional utility application filed on March 14, 2014, and assigned application number 14/214,433, and entitled "Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride", that claims priority to application (i) above;
- (iii) A United States non-provisional utility application filed on September 14, 2015, and assigned application number 14/776,624, and entitled "Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride", that claims priority to application (i) above;
- (iv) A Taiwan application filed on March 14, 2014, and assigned application number 103109816, and entitled "Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride", that claims priority to application (i) above;
- (v) A Venezuela application filed on March 14, 2014, and assigned application number 2014-000391, and entitled "Eutectic Formulations of Cyclobenzaprine

Hydrochloride and Amitriptyline Hydrochloride”, that claims priority to application (i) above; and

- (vi) An International Patent Application that claims priority to application (i) above, filed under the Patent Cooperation Treaty on March 14, 2014 and assigned serial number PCT/US2014/029872 entitled “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride”, designating all PCT member states, including Albania (AL), Algeria (DZ), Angola (AO), Antigua & Barbuda (AG), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Bahrain (BH), Barbados (BB), Belarus (BY), Belgium (BE), Belize (BZ), Benin (BJ), Bosnia and Herzegovina (BA), Botswana (BW), Brazil (BR), Bulgaria (BG), Brunei Darussalam (BN), Burkina Faso (BF), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), Chile (CL), China (CN), Colombia (CO), Congo (CG), Costa Rica (CR), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czech Republic (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Dominica (DM), Dominican Republic (DO), Ecuador (EC), Egypt (EG), El Salvador (SV), Equatorial Guinea (GO), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Greece (GR), Grenada (GD), Guatemala (GT), Guinea (GN), Guinea Bissau (GW), Honduras (HN), Hungary (HU), Iceland (IS), India (IN), Indonesia (ID), Ireland (IE), Islamic Republic of Iran (IR), Israel (IL), Italy (IT), Japan (JP), The Comoros (KM), Kazakhstan (KZ), Kenya (KE), Kyrgyzstan (KG), Lao People's Democratic Republic (LA), Latvia (LV), Lesotho (LS), Liberia (LR), Libyan Arab Jamahriya (LY), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), former Yugoslav Republic of Macedonia (MK), Malawi (MW), Malaysia (MY), Mali (ML), Malta (MT), Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Montenegro (ME), Morocco (MA), Mozambique (MZ), Namibia (NA), Netherlands (NL), New Zealand (NZ), Nicaragua (NI), Niger (NE), Nigeria (NG), Norway (NO), Oman (OM), Panama (PA), Papua New Guinea (PG), Peru (PE), the Philippines (PH), Poland (PL), Portugal (PT), Qatar (QA), Republic of Korea (KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU), Rwanda (RW), Saint

Lucia (LC), Saint Kitts and Nevis (KN), Saint Vincent and the Grenadines (VC), San Marino (SM), São Tomé and Príncipe (ST), Saudi Arabia (SA), Senegal (SN), Serbia (RS), Seychelles (SC), Sierra Leone (SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland (CH), Syrian Arab Republic (SY), Tajikistan (TJ), United Republic of Tanzania (TZ), Togo (TG), Thailand (TH), Trinidad and Tobago (TT), Tunisia (TN), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab Emirates (AE), United Kingdom (GB), United States of America (US), Uzbekistan (UZ), Viet Nam (VN), Zambia (ZM) and Zimbabwe (ZW);

including any applications and patents claiming priority therefrom, and any renewals, revivals, reissues, reexaminations, extensions, supplementary protection certificates, continuations and divisions thereof, and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of TONIX PHARMACEUTICALS, INC., its designee, or in our name at TONIX PHARMACEUTICALS, INC. or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent that claims priority therefrom in the United States or in any other country of the world and any renewals, revivals, reissues, reexaminations, supplementary protection certificates, and extensions of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to TONIX PHARMACEUTICALS, INC. as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of TONIX PHARMACEUTICALS, INC. to execute and to deliver to TONIX PHARMACEUTICALS, INC. any additional applications for patents for said inventions

and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations, extensions, supplementary protection certificates, and substitute applications thereof.

We further agree at any time to execute and to deliver upon request of TONIX PHARMACEUTICALS, INC. such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of TONIX PHARMACEUTICALS, INC. under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNOR:

REDOX srl

Quichevi Roberts
Name:

Title:

Date: 17/05/2016

WITNESSES:

[Signature]
Name:

17/5/16
Date

[Signature]
Name:

17/5/16
Date

ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Assignment on behalf of TONIX PHARMACEUTICALS, INC.

By: Seth Lederman
Name:
Title:

Date: 5/23/16

State of New York)
County of New York)

On this 23 day of May, 2016, before me, the undersigned notary public, personally appeared Seth Lederman proved to me through satisfactory evidence of identification, which was NY Driver License, to be the person whose name is signed on the preceding or attached document in my presence.

(SEAL) MARY C GREATHEAD
NOTARY PUBLIC-STATE OF NEW YORK
No. 81GR6330341
Qualified in New York County
My Commission Expires September 14, 2019

Mary C. Greathead
Notary Public

My commission expires 09/14/19